source
- Tiziana Life Sciences CEO Ivor Elrifi boosts stake, buying 321,423 shares at $1 eachTiziana Life Sciences announced that its chief executive officer, Ivor Elrifi, purchased 321,423 common shares of the company on NASDAQ at $1.00 per share. The purchase raises his total holding to…
- Vistagen's anxiety nasal spray fails to outperform placebo in phase 2 trialVistagen Therapeutics reported that its experimental nasal spray fasedienol did not show a statistically significant advantage over placebo in a phase 2 study of social anxiety disorder. The trial…Fierce Biotech · 14d agoNegative readoutNegative